## Accepted Manuscript

Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib

Man Tong, Noélia Che, Lei Zhou, Steve T. Luk, Phillis W. Kau, Stella Chai, Elly S. Ngan, Chung-Mau Lo, Kwan Man, Jin Ding, Terence K. Lee, Stephanie Ma


PII: S0168-8278(18)32119-6

DOI: https://doi.org/10.1016/j.jhep.2018.05.034

Reference: JHEPAT 6996

To appear in: Journal of Hepatology

Received Date: 30 January 2018 Revised Date: 26 April 2018 Accepted Date: 23 May 2018



Please cite this article as: Tong, M., Che, N., Zhou, L., Luk, S.T., Kau, P.W., Chai, S., Ngan, E.S., Lo, C-M., Man, K., Ding, J., Lee, T.K., Ma, S., Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib, *Journal of Hepatology* (2018), doi: https://doi.org/10.1016/j.jhep.2018.05.034

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## ACCEPTED MANUSCRIPT

Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and

regorafenib

Man TONG<sup>1</sup>, Noélia CHE<sup>1</sup>, Lei ZHOU<sup>1</sup>, Steve T LUK<sup>1</sup>, Phillis W KAU<sup>1</sup>, Stella CHAI<sup>1</sup>,

Elly S NGAN<sup>3</sup>, Chung-Mau LO<sup>2,3</sup>, Kwan MAN<sup>2,3</sup>, Jin DING<sup>5</sup>, Terence K LEE<sup>2,5</sup>, Stephanie MA<sup>1,2</sup>

<sup>1</sup>School of Biomedical Sciences, Li Ka Shing Faculty of Medicine and <sup>2</sup>State Key Laboratory for Liver

Research, University of Hong Kong, Pokfulam, Hong Kong; <sup>3</sup>Department of Surgery, University of Hong

Kong, Queen Mary Hospital, Pokfulam, Hong Kong; <sup>4</sup>International Cooperation Laboratory on Signal

Shanghai, China; <sup>5</sup>Department of Applied Biology & Chemical Technology, Hong Kong Polytechnic

University, Hong Kong,

Transduction, Eastern Hepatobiliary Surgery Hospital/Institute, Second Military Medical University,

Correspondence: Dr. Stephanie Ma, PhD, School of Biomedical Sciences, Li Ka Shing Faculty of

Medicine, The University of Hong Kong, Room 47, 1/F, Laboratory Block, 21 Sassoon Road, Pokfulam,

Hong Kong. E-mail: stefma@hku.hk.

**Keywords:** sorafenib resistance; regorafenib; liver cancer; ANXA3; antibody therapy

**Conflict of interest:** The authors have nothing to disclose.

Financial support: This work was funded by the National Natural Science Foundation of China -

General Program (81672456), Research Grants Council of Hong Kong - Collaborative Research Fund

(C7027-14G) and — Theme Based Research Scheme (T12-710/16-R). Stephanie Ma is a recipient of the

Croucher Innovation Award from the Croucher Foundation.

Author contributions: M.T. and S.M. conceived the project. M.T. performed the research, analyzed

and interpreted the data with the assistance of N.C. who helped with autophagy-related and animal

studies, L.Z. who helped with the organoid and animal studies, S.T.L. who helped with the in vitro

functional studies, P.K. who helped with the transmission electron microscopy tissue processing and

S.C. who helped with intrahepatic injections. E.N. contributed thyroid cell line and reagents. C.M.L.

1

## Download English Version:

## https://daneshyari.com/en/article/10218106

Download Persian Version:

https://daneshyari.com/article/10218106

Daneshyari.com